Insmed Incorporated (NASDAQ:INSM) Shares Acquired by Ensign Peak Advisors Inc

Ensign Peak Advisors Inc increased its position in shares of Insmed Incorporated (NASDAQ:INSM) by 9.3% in the fourth quarter, HoldingsChannel.com reports. The firm owned 529,049 shares of the biopharmaceutical company’s stock after acquiring an additional 44,928 shares during the quarter. Ensign Peak Advisors Inc’s holdings in Insmed were worth $36,526,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of INSM. Deutsche Bank AG boosted its position in shares of Insmed by 76.6% during the 4th quarter. Deutsche Bank AG now owns 488,966 shares of the biopharmaceutical company’s stock worth $33,758,000 after acquiring an additional 212,024 shares in the last quarter. Driehaus Capital Management LLC increased its stake in Insmed by 2.3% in the fourth quarter. Driehaus Capital Management LLC now owns 171,289 shares of the biopharmaceutical company’s stock valued at $11,826,000 after purchasing an additional 3,859 shares during the last quarter. Duquesne Family Office LLC raised its holdings in Insmed by 2,867.4% during the fourth quarter. Duquesne Family Office LLC now owns 593,470 shares of the biopharmaceutical company’s stock worth $40,973,000 after purchasing an additional 573,470 shares in the last quarter. Cetera Investment Advisers lifted its position in shares of Insmed by 15.0% during the 4th quarter. Cetera Investment Advisers now owns 10,154 shares of the biopharmaceutical company’s stock worth $701,000 after buying an additional 1,321 shares during the last quarter. Finally, Cantor Fitzgerald L. P. purchased a new stake in shares of Insmed during the 4th quarter worth approximately $682,000.

Insmed Stock Performance

Shares of INSM stock opened at $65.08 on Friday. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The stock has a 50 day simple moving average of $72.37 and a 200-day simple moving average of $73.27. The company has a market cap of $11.83 billion, a price-to-earnings ratio of -11.64 and a beta of 0.84. Insmed Incorporated has a 12-month low of $21.92 and a 12-month high of $84.91.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) EPS for the quarter, missing analysts’ consensus estimates of ($1.36) by ($0.06). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The business had revenue of $92.82 million during the quarter, compared to analyst estimates of $91.63 million. During the same period last year, the business posted ($1.06) EPS. Insmed’s revenue was up 22.9% compared to the same quarter last year. On average, equities analysts forecast that Insmed Incorporated will post -4.56 EPS for the current year.

Insider Buying and Selling

In related news, CEO William Lewis sold 18,750 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $81.03, for a total value of $1,519,312.50. Following the sale, the chief executive officer now directly owns 334,186 shares of the company’s stock, valued at approximately $27,079,091.58. This represents a 5.31 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Roger Adsett sold 42,975 shares of the firm’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $78.61, for a total transaction of $3,378,264.75. Following the transaction, the chief operating officer now owns 146,082 shares of the company’s stock, valued at $11,483,506.02. This trade represents a 22.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 182,337 shares of company stock valued at $14,284,557. Corporate insiders own 3.00% of the company’s stock.

Analysts Set New Price Targets

INSM has been the topic of several research analyst reports. UBS Group cut their price target on shares of Insmed from $110.00 to $109.00 and set a “buy” rating on the stock in a research note on Friday. Guggenheim reissued a “buy” rating and issued a $101.00 target price on shares of Insmed in a report on Tuesday, February 25th. Cantor Fitzgerald restated an “overweight” rating on shares of Insmed in a research note on Wednesday, February 19th. Bank of America boosted their price objective on Insmed from $92.00 to $96.00 and gave the company a “buy” rating in a research note on Thursday, March 20th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $90.00 target price on shares of Insmed in a report on Tuesday, April 22nd. One analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $93.93.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.